Clinical data
AHFS/ International Drug Names
Routes of
ATC code R05DB03 (WHO)
Legal status
Legal status
  • Withdrawn
CAS Number 14860-49-2 YesY
PubChem (CID) 26937
DrugBank DB09004 N
ChemSpider 25085 YesY
KEGG D07716 YesY
ECHA InfoCard 100.035.373
Chemical and physical data
Formula C14H22ClNO
Molar mass 255.783 g/mol
3D model (Jmol) Interactive image
Chirality Racemic mixture
 NYesY (what is this?)  (verify)

Clobutinol is a cough suppressant distributed by Boehringer-Ingelheim, Novartis's Hexal (Sandoz), Stada and possibly other companies.

Side effects and withdrawal

Studies in 2004 had indicated that clobutinol has the potential to prolong the QT interval.[1] Clobutinol was in 2007 determined to cause cardiac arrhythmia in some patients.[2]

Boehringer Ingelheim products containing clobutinol were voluntarily withdrawn from sale in Germany, and the rest of the world, on August 31, 2007.[3]

The approval for Germany and the EU was revoked in 2008.[4]

See also


  1. Bellocq, C.; Wilders, R.; Schott, J. J.; Louérat-Oriou, B.; Boisseau, P.; Le Marec, H.; Escande, D.; Baró, I. (2004). "A Common Antitussive Drug, Clobutinol, Precipitates the Long QT Syndrome 2". Molecular Pharmacology. 66 (5): 1093–1102. doi:10.1124/mol.104.001065. PMID 15280442.
  2. "Clobutinol-haltige Arzneimittel: BfArM ordnet Widerruf der Zulassung an.". BfArM (German Federal Institute for Drugs and Medical Devices). 2007-08-31. Clobutinol: BfArM orders cancellation of approval
  3. "Boehringer Ingelheim voluntarily withdraws its clobutinol containing medications.". Boehringer Ingelheim. 2007-08-31.
  4. "Cancellation of approval" (pdf). BfArM (German Federal Institute for Drugs and Medical Devices). 2008-06-06. Die Zulassungen für die o.g. Arzneimittel werden mit sofortiger Wirkung widerrufen.
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.